Beleggen.nl Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

GTCB - GTC Biotherapeutics - Deel 9

2.021 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 102 »» | Laatste | Omlaag ↓
  1. [verwijderd] 3 april 2007 21:09
    quote:

    robertix schreef:

    elke dag 4 cent erbij is eind mei goed voor $2.25........
    En dan hebben we nog juni voor de deur,
    hier wil ik voor tekenen !!!

    1.17
  2. [verwijderd] 3 april 2007 21:12
    quote:

    psycho-pharma schreef:

    [quote=plausibel]
    1,15

    ja idd saai
    [/quote]

    Gaaaaaaaaaaappppppp: 1.16

    (++7 cents)

    P.
    Snuuuuuuuuuurk: 3.41

    Shit, in slaap gevallen.

    1.18

    P.
  3. orchid 3 april 2007 21:23
    ben echt benieuwd wat er nu aan de hand is, las op buitenlandse sites dat er ook mondelinge mededelingen gedaan worden door GTCB.
  4. [verwijderd] 3 april 2007 21:52
    er staat zeker iets te gebeuren volgens mij,
    het is toch niet mogelijk dat we maanden aanmodderen , en nu met een sprongen omhoog gaan,
    nee,,,,,dit is zonder echt aankomend nieuws niet normaal. (ook gelet op de recente aankoop van de topman)

    vol verwachting klopt mijn hart.......
  5. [verwijderd] 3 april 2007 22:06
    quote:

    Beurs-kneus schreef:

    er staat zeker iets te gebeuren volgens mij,
    het is toch niet mogelijk dat we maanden aanmodderen , en nu met een sprongen omhoog gaan,
    nee,,,,,dit is zonder echt aankomend nieuws niet normaal. (ook gelet op de recente aankoop van de topman)

    vol verwachting klopt mijn hart.......

    wat heb ik nu weer gemist, welke topman heeft hoeveel aandelen gekocht?

    dank.

    mvg
  6. [verwijderd] 3 april 2007 22:19
    quote:

    connect schreef:

    [quote=Beurs-kneus]
    er staat zeker iets te gebeuren volgens mij,
    het is toch niet mogelijk dat we maanden aanmodderen , en nu met een sprongen omhoog gaan,
    nee,,,,,dit is zonder echt aankomend nieuws niet normaal. (ook gelet op de recente aankoop van de topman)

    vol verwachting klopt mijn hart.......

    [/quote]

    wat heb ik nu weer gemist, welke topman heeft hoeveel aandelen gekocht?

    dank.
    mvg
    GTC BIOTHERAPEUTICS INC OFF 03/14/2007 Form 4 B D 24,000 $0.990 228,694

    t-is maar 24K maar voor mij gaat het meer om de intentie!

    B.K.
    24 k voor the chief COX GEOFFREY niet veel, voor mij mijn totale aantal.........
  7. ludwig mack 4 april 2007 16:18
    Laatste 1,13
    Laatste volume 100
    Tijd 16:17
    +/- -0,01 -0,88%
    Volume 81.546

    Bied
    Biedvolume
    Laat
    Laatvolume

    Slot 1,14 3/4
    Open 1,15 15:30
    Hoog 1,17 15:38
    Laag 1,11 15:54

  8. [verwijderd] 4 april 2007 16:35
    quote:

    SkySpam1 schreef:

    Breaking News !!!

    Phase II
    Study of MM-093 to Treat Patients With Patients With Uveitis
    This study is currently recruiting patients.
    clinicaltrials.gov/ct/search;jsession...
    Last Updated: March 7, 2007

    Nog ""niet"" aangepast op hun site !!
    www.merrimackpharma.com/pipeline/inde...

    Voor wie zich geroepen voelt, deze op Ihub en eventueel YB te plaatsen.
    Met dank !!
    Zoals ik hier op 10 maart reeds kwam te schrijven,
    is met deze, vandaag bevestigd !!

    Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Pilot Study of MM-093 in Patients with Autoimmune Uveitis.
    biz.yahoo.com/prnews/070404/new007.ht...

  9. [verwijderd] 4 april 2007 16:39

    Press Release Source: Merrimack Pharmaceuticals, Inc.
    tinyurl.com/2yfs7v

    Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Pilot Study of MM-093 in Patients with Autoimmune Uveitis
    Wednesday April 4, 8:30 am ET

    CAMBRIDGE, Mass., April 4 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced the initiation of a Phase 2 pilot study to determine the safety and efficacy of its immunomodulator MM-093 in patients suffering from autoimmune uveitis. MM-093, Merrimack's lead product, is a recombinant version of human alpha-fetoprotein (AFP).


    Uveitis is an autoimmune inflammatory disease that produces eye pain, light sensitivity, and diminished vision, including blindness. Sarcoid and birdshot are rare uveitis subtypes, which could be classified as Orphan indications due to their small patient size.

    The randomized, double-blind, placebo-controlled, Phase 2 study is being conducted at the Massachusetts Eye Research and Surgery Institute in Cambridge, Massachusetts under the direction of C. Stephen Foster, MD, a world-renowned expert in uveitis and Clinical Professor of Ophthalmology at Harvard Medical School. The objective of this study is to examine the safety and efficacy of MM-093 in approximately 20 patients with either sarcoid or birdshot uveitis. Patients will discontinue their current therapy for uveitis and be treated with MM-093 or placebo for up to 36 weeks. This study is a flare design where the number of patients whose uveitis relapses after discontinuing the use of their background therapy will be assessed at the end of the study. Patients who experience a flare of uveitis during the study will be retreated with their original therapy.

    "Uveitis remains a significant cause of blindness in developed countries, and immunosuppressive chemotherapy and systemic corticosteroid therapy continue to form the backbone for ocular immunologists trying to preserve the vision of patients who are going blind from uveitis. However, such therapies can cause significant, potentially serious side effects," said Dr. Foster, principal investigator for the study. "MM-093 is a particularly promising immunomodulatory molecule from a risk/benefit standpoint, with very little likelihood of exposing patients to the side effects of corticosteroid or of immunosuppressive therapy."

    Merrimack controls a strong intellectual property estate around MM-093 including fourteen issued patents and a number of pending applications, both in the U.S. and internationally, which cover composition of matter, production methods and therapeutic uses of the drug.

    Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis, psoriasis or with autoimmune uveitis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately held company based in Cambridge, Massachusetts. For additional information, please visit www.merrimackpharma.com.

    Contact: Kathleen Petrozzelli, Manager, Corporate Communications, 617- 441-1043

    --------------------------------------------------------------------------------
    Source: Merrimack Pharmaceuticals, Inc.

    tinyurl.com/2yfs7v
2.021 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 102 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.194
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.502
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.648
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.991
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.319
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.709
AMG 971 133.045
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 482
Antonov 22.632 153.605
Aperam 92 14.905
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.559
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.980
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.609
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390